EyeGate receives FDA approval to initiate PRK pivotal study
By Akshay Kedari  Date: 2019-06-04

EyeGate receives FDA approval to initiate PRK pivotal study

EyeGate Pharmaceuticals, Inc. has reportedly received approval from the U.S. Food and Drug Administration to start photorefractive keratectomy or PRK pivotal study.

As per trusted sources, the FDA has determined that EyeGate provided adequate data to support the initiation of the clinical study and has asked the pharma company to make some alterations in the patient informed consent document before enrollment. Sources claim that the company will immediately address these changes and looks forward to enrollments starting this month.

Sources familiar with the knowledge of the matter cite Stephen From, Chief Executive Officer of EyeGate, to have said in a statement that the company is extremely pleased with the comments received from the FDA about the design of the company’s PRK pivotal study and plans to initiate enrollment at the earliest.

The company expects topline outcomes by the end of 2019, anticipating them to be positive, so that the de novo application for commercialization can be submitted soon, From claimed, adding that post the successful approval, the company’s OGB platform will be the United States’ foremost prescription Hyaluronic Acid eyedrop formulation presenting a huge opportunity for the company.

According to a reliable news report, EyeGate Pharmaceuticals Inc. stock spiked 20% as of June 3. The company’s stock has reportedly climbed $0.05 from the earlier closing price of $0.25 on a volume of 3,160,386 stocks.

For the record, EyeGate is a clinical-stage specialty pharmacological company dedicated to developing and commercializing drugs and therapeutics through its two proprietary platform technologies focused on the treatment of eye diseases and disorders.

The company’s OBG platform formed on a crosslinked thiolated CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that holds unique physical and chemical features such as hydrating and healing properties when applied to the ocular surface, reported sources. 

Source Credit
https://finance.yahoo.com/news/eyegate-receives-approval-fda-initiate-105500530.html

https://www.investorsobserver.com/market-intelligence-center/stock-update/is-eyegate-pharmaceuticals-eyeg-stock-a-strong-buy-following-fda-study-approval/


 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Rivian secures USD 2.65 billion months before its first vehicle launch
Rivian secures USD 2.65 billion months before its first vehicle launch
By Akshay Kedari

Electric vehicle startup, Rivian, backed by Ford Motor Co. and Amazon.com Inc., has reportedly announced an investment round of USD 2.65 billion led by T. Rowe Price, months before its first vehicle launch. Sources with knowledge of the matter state...

BMW drivers can now unlock and start cars without using their iPhone
BMW drivers can now unlock and start cars without using their iPhone
By Akshay Kedari

German multinational automobile manufacturer, Bayerische Motoren Werke AG, commonly known as BMW, has reportedly unveiled an upgraded version of its mobile car key technology, called the Digital Key Plus. This product enables iPhone users to unlock t...

FMCG firms resort to marginal hike to cope with raw material inflation
FMCG firms resort to marginal hike to cope with raw material inflation
By Akshay Kedari

The recent inflation in raw materials has reportedly prompted players in the FMCG sector to take price hike measures for their products, in a bid to maintain the revenues. According to reliable sources, some FMCG companies, including Marico, have al...

boAt raises USD 100 million in funding from Warburg Pincus
boAt raises USD 100 million in funding from Warburg Pincus
By Akshay Kedari

Indian consumer electronics brand, boAt, has reportedly secured funding of USD 100 million from Warburg Pincus, a New-York-based private equity firm, at a USD 300 million valuation. The company will utilize these funds to expand its product portfoli...

Elevar Therapeutics and Inceptua partner to commercialize Apealea®
Elevar Therapeutics and Inceptua partner to commercialize Apealea®
By Akshay Kedari

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel tre...